These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15597069)

  • 1. Global epidemiology of meningococcal disease and vaccine efficacy.
    Pollard AJ
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S274-9. PubMed ID: 15597069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serogroup A meningococcal conjugate vaccines in Africa.
    Kristiansen PA; Jørgensen HJ; Caugant DA
    Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meningococcal vaccines.
    Danzig L
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S285-92. PubMed ID: 15597071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epidemiology of meningococcal disease and the impact of vaccines.
    Khatami A; Pollard AJ
    Expert Rev Vaccines; 2010 Mar; 9(3):285-98. PubMed ID: 20218857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations.
    Baker CJ
    J Adolesc Health; 2016 Aug; 59(2 Suppl):S29-37. PubMed ID: 27449147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
    Pollard AJ; Green C; Sadarangani M; Snape MD
    Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
    [No Abstract]   [Full Text] [Related]  

  • 11. Quadrivalent meningococcal conjugate vaccines.
    Pace D; Pollard AJ; Messonier NE
    Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we control all-cause meningococcal disease in Europe?
    Sadarangani M; Pollard AJ
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S103-S112. PubMed ID: 27129415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results.
    MacLennan JM; Rodrigues CMC; Bratcher HB; Lekshmi A; Finn A; Oliver J; Wootton M; Ray S; Cameron C; Smith A; Heath PT; Bartolf A; Nolan T; Hughes S; Varghese A; Snape MD; Sewell R; Cunningham R; Stolton A; Kay C; Palmer K; Baxter D; Suggitt D; Zipitis CS; Pemberton N; Jolley KA; Bray JE; Harrison OB; Ladhani SN; Pollard AJ; Borrow R; Gray SJ; Trotter C; Maiden MCJ
    Lancet Infect Dis; 2021 May; 21(5):677-687. PubMed ID: 33482143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.
    Maiden MC; Ibarz-Pavón AB; Urwin R; Gray SJ; Andrews NJ; Clarke SC; Walker AM; Evans MR; Kroll JS; Neal KR; Ala'aldeen DA; Crook DW; Cann K; Harrison S; Cunningham R; Baxter D; Kaczmarski E; Maclennan J; Cameron JC; Stuart JM
    J Infect Dis; 2008 Mar; 197(5):737-43. PubMed ID: 18271745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal disease.
    Memish ZA; Alrajhi AA
    Saudi Med J; 2002 Mar; 23(3):259-64. PubMed ID: 11938412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
    Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK
    Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunisation update: Meningococcal B and ACWY vaccines.
    Davidson GT; Heaton PA; Paul SP
    J Fam Health; 2015; 25(6):22-5. PubMed ID: 26749934
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.